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Summary
QUESTIONS UNDER STUDY: The aim of this study was
to evaluate two practices of airway management in patients
undergoing head and neck cancer (HNC) resection and mi-
crovascular free tissue transfer (MFTT), and to assess the
advantages and disadvantages of the two approaches.
METHODS: Patients undergoing a delayed extubation ap-
proach (NO-TRACH group) and patients undergoing
primary tracheotomy (PRIM-TRACH group) were retro-
spectively evaluated in terms of perioperative and post-
operative outcome measures.
RESULTS: Not performing routine tracheotomy was safe
and no perioperative airway complications occurred. NO-
TRACH patients were extubated after 1.1 ± 0.9 days (mean
± standard deviation) and secondary tracheotomy was ne-
cessary in three patients (13%). NO-TRACH patients re-
vealed decreased duration of surgery (p <0.05) and showed
trends to earlier resumption of oral feeding and decreased
length of hospitalisation. Flap complication rates were sim-
ilar in both groups, with an overall flap survival rate of
97.5% (n = 39/40).
CONCLUSIONS: With appropriate postoperative care,
carefully selected patients undergoing major HNC resec-
tions with MFTT can be safely managed without routine
tracheotomy.
Key words: head and neck cancer; microvascular free
tissue transfer; alternative airway management; delayed
extubation, routine tracheotomy
Introduction
Airway management in head and neck cancer (HNC) pa-
tients undergoing major surgical procedures, including mi-
crovascular free tissue transfer (MFTT), has often been
routine tracheotomy. The necessity of this procedure has,
however, been questioned [1, 2].
Proponents of routine tracheotomy argue that extensive
HNC resection combined with MFTT is a major surgical
procedure with long operative times and often performed
on poly-morbid patients. Hence, the anatomical and
physiological impact should not be underestimated [3]. La-
ryngopharyngeal oedema, posterior tongue oedema, swell-
ing of the free flap, haemorrhage and phlegm accumulation
can all potentially cause airway compromise. These con-
cerns are particularly pressing in surgically treated oro-
pharyngeal cancer. Furthermore, tracheotomy can help im-
prove access to the primary tumour intraoperatively.
Proponents of not performing routine tracheotomy argue that,
when performed in the appropriately experienced centres,
even major HNC resection and MFTT is reliable and predict-
able. The perioperative mortality rate is reported to be around
1.1% and free flap failure rates are similarly low [3–5]. Even
in elderly patients, MFTT is considered a safe procedure with
similar complication rates to those in younger patients [4, 5].
Appropriate postoperative vigilance allows patients to avoid
routine tracheotomy in the knowledge that later airway inter-
ventions can be performed if necessary.
Furthermore, it should be remembered that tracheotomy it-
self is not without complications, with rates as high as 4.1%
to 8% in some series [6–8]. Possible complications include
haemorrhage, obstruction, cannula displacement, local in-
fection, pneumonia, fistula, tracheal stenosis and tumour
recurrence due to tumour seeding [6, 9]. Also, average time
to decannulation in patients with routine tracheotomy can
be prolonged and the effect of tracheotomy on functional
rehabilitation is difficult to quantify [10].
In an effort to reduce operative time and morbidity, and
speed functional recovery, several authors have, therefore,
presented evidence that routine tracheotomy is not always
required [1, 2]. For example, Brickman et al. argued that
maxillectomy and MFTT does not negatively impact a pa-
tient’s oropharyngeal airway and that elective tracheotomy
should only be considered in patients with additional risk
factors, such as cardiopulmonary diseases [2]. Indeed, out-
side of trauma and cancer settings, for example in bimaxil-
lary advancement for cleft palate, routine tracheotomy is far
less common.
Balancing the benefits and risks of routine tracheotomy to
a specific patient is clearly no simple exercise. Recently, a
Swiss Medical Weekly · PDF of the online version · www.smw.ch Page 1 of 8
tracheotomy scoring system to guide airway management
after major head and neck surgery has been proposed,
whereby tumour site, mandibulectomy, neck dissection and
reconstruction are scoring factors [11]. However, this score
requires further assessment in a prospective randomised
controlled trial and a larger group of patients. In this con-
text we present a retrospective case series analysis, evalu-
ating both the traditional tracheotomy approach and the al-
ternative delayed extubation approach.
Material and methods
A retrospective study was performed on consecutive HNC
patients in the Department of Otorhinolaryngology
(University Hospital, Zurich, Switzerland) between April
2011 and January 2013. All patients were discussed in
our multidisciplinary tumour board meeting and staged in
accordance with the latest version of the American Joint
Committee on Cancer (AJCC) guidelines [12]. Inclusion
criteria for this study were all HNC patients undergoing
HNC resection with curative intent and reconstruction with
MFTT. Primary tumours were located in the oral cavity,
oropharynx, hypopharynx, larynx and salivary glands. Two
patients were excluded from the study because they had
pre-existing tracheostomies.
In April 2012, we changed from routine tracheotomy to
prolonged intubation. Thus, the observation period was
characterised by patients undergoing MFTT with (before
April 2012) and without (after April 2012) routine
tracheotomy. Patients with a transmandibular approach,
segmental mandibular resection, maxillectomy or under-
going laryngopharyngectomy were excluded from the pro-
longed intubation approach.
Patient’s case records were reviewed for demographic data
(gender, age at the time of operation), TNM staging, tu-
mour histology, primary tumour site and outcome meas-
ures: overall survival (OS), disease specific survival (DSS)
and any recurrence free survival (ARFS). With regard to
MFTT, we analysed the type of the free tissue flap and flap
complications (anastomosis revision, flap wound revision,
complications in the further course of treatment, donor site
complications). Furthermore, we reviewed patient data for
duration of surgery, length of postoperative stay on the in-
tensive care unit (ICU), length of stay on the intermediate
care unit (IMCU), length of postoperative dependence on
artificial nutrition (nasogastric tube vs percutaneous endo-
scopic gastrostomy vs total parenteral nutrition) and overall
length of hospital stay. With regard to airway management
we reviewed patient data for tracheotomy: no tracheotomy
vs primary tracheotomy vs secondary tracheotomy. Dura-
tion of intubation for patients undergoing prolonged intub-
ation without primary tracheotomy was noted.
Statistical analysis
A total of 40 patients met inclusion criteria. They were split
into two groups, namely patients with no tracheotomy or
secondary tracheotomy (n = 23; NO-TRACH group) and
patients with primary tracheotomy (n = 17; PRIM-TRACH
group).
Data were expressed as mean ± standard deviation (SD) or
median and interquartile range (IQR) as appropriate. Be-
cause of the small sample size and non-normally distrib-
uted data we used nonparametric statistics (Mann-Whitney
Test) to test differences between the two groups. Surviv-
al rates were estimated by the Kaplan-Meier method and
compared using a log-rank test if appropriate. A p-value
<0.05 was considered statistically significant.
When comparing dependence on artificial nutrition in both
groups, the analysis was based on a subset of patients (n =
35) that excluded those who remained dependent on artifi-
cial nutrition until the present day or those who died in the
follow-up.
In an exploratory analysis, we also investigated the dif-
ference in any complications (yes/no) with type of airway
management (NO-TRACH vs PRIM-TRACH) using a re-
gression modelling approach. The analysis was based on
a subset of patients (n = 37) that excluded those with a
secondary tracheotomy. To adjust for potential differences
in the prognostic profile between patients receiving one of
the two airway management approaches, we estimated the
risk for each patient of a complication (dependent variable)
based on the patient’s age, gender and tumour stage (inde-
pendent variables) by means of a multivariate logistic re-
gression analysis. In a second logistic regression analysis
using complications as the dependent variable, the vari-
able containing the prognostic probability of a complic-
ation based on these three parameters was entered along
with an indicator variate for type of airway management
approach. Thus, we made the two groups comparable in
terms of age, gender and tumour stage. Statistical analyses
were made using the Stata 11.2 statistics software pack-
age (StataCorp. 2009. Stata Statistical Software: Release
11. College Station, TX: StataCorp LP.).
Results
Assessment of demographic data
Between April 2011 and January 2013, 42 patients HNC
patients underwent HNC resection and reconstruction with
MFTT at our department. Two patients were excluded from
the study because they had pre-existing tracheostomies.
Consequently, the total study population consisted of 40
patients: 29 male patients (72.5%) and 11 female patients
(27.5%). Eighteen male patients (78.3%) and 5 female pa-
tients (21.7%) were in the NO-TRACH group, compared
with 11 male patients (64.7%) and 6 female patients
Figure 1
Distribution of flap donor sites in all reviewed patients undergoing
microvascular free tissue transfer.
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(35.3%) in the PRIM-TRACH group. At the time of oper-
ation, the mean age of all patients was 65.1 ± 10.8 years,
with the oldest patient being 90 years old and the youngest
patient being 39 years old. The mean age in the NO-
TRACH group was 64.5 ± 11.0 years compared with 65.8
± 10.9 years in the PRIM-TRACH group (p = 0.79) (table
1).
TNM staging, histological workup and site of primary
tumour
Histological workup of all 40 patients showed squamous
cell carcinoma in 33 patients (82.5%), adenocarcinoma in 4
patients (10.0%), acinus-cell carcinoma in 1 patient (2.5%),
mucoepidermoid carcinoma in 1 patient (2.5%) and
spindle-cell like carcinoma in 1 patient (2.5%). Sites of
primary tumours were: oral cavity (24 patients; 60.0%),
oropharynx (9 patients; 22.5%), parotid gland (2 patients;
5.0%), subglottic and supraglottic larynx (2 patients;
5.0%), hard palate and maxilla (1 patient; 2.5%), floor of
the nose (1 patient; 2.5%) and sublingual gland (1 patient;
2.5%). Two patients in the PRIM-TRACH group under-
went neoadjuvant chemotherapy prior to surgical resection
and MFTT. Seven patients of the PRIM-TRACH group and
one patient of the NO-TRACH group received salvage sur-
gery as a result of tumour persistence or tumour recurrence
after a nonsurgical primary treatment approach. Table 1
provides detailed information on patient and tumour char-
acteristics for each group separately.
Duration of surgery, tracheotomy, postoperative
management
Duration of surgery, tracheotomy
Compared with the PRIM-TRACH group, the duration of
surgery in the NO-TRACH group was significantly less
(8.2 ± 1.6 hours vs 10.4 ± 2.7 hours; p = 0.001) (table
2). In 20 of 23 patients in the NO-TRACH group there
was no need for secondary tracheotomy (87%). In three
patients (13%), secondary tracheotomy was performed, in
one patient for revision of the neck due to extended cervical
haematoma on the first postoperative day and in two pa-
tients owing to cardiopulmonary decompensation and the
need for long-term intubation on the third and sixth post-
operative day, respectively. In the PRIM-TRACH group,
tracheotomy was performed at the start of the procedure in
all 17 patients (table 1).
ICU/IMCU care
Postoperatively, 21/23 patients (91.3%) of the NO-TRACH
group and 14/17 patients (82.4%) of the PRIM-TRACH
group received further care on the ICU. The ICU length of
stay in the NO-TRACH group was similar to the PRIM-
TRACH group (median 1.0 days, IQR 1–2 vs median 2.0
days, IQR 1–3, p = 0.27). On average, delayed extubation
of the NO-TRACH patients was performed after 1.1 ±
0.9 days (excluding those patients with secondary
tracheotomy). Consequently, patients of both groups were
transferred to the IMCU, with similar outcome in terms
of IMCU stay: median 1.0 days, IQR 1–2 in the PRIM-
TRACH group vs median 1.0 days, IQR 1–1 in the NO-
TRACH group (p = 0.58). Two patients in the NO-TRACH
and three patients of the PRIM-TRACH group proceeded
directly to the IMCU on the day of operation, without any
ICU stay (table 2).
Postoperative nutrition
In terms of postoperative nutrition, the PRIM-TRACH
group showed a trend to longer dependence on artificial nu-
trition compared with the NO-TRACH (median 15.0 days,
IQR 9–55 vs median 9.0 days, IQR 8–18; p = 0.07) (table
2). Five of the PRIM-TRACH patients remained dependent
on artificial nutrition until last follow-up or until their
death, whereas all patients of the NO-TRACH group were
ultimately able to be orally fed.
Hospital length of stay
Again our results show a (nonsignificantly) shorter median
length of hospital stay in the NO-TRACH group compared
with the PRIM-TRACH group (15.0 days, IQR 10–21 vs
18.0 days, IQR 14–22, p = 0.14) (table 2).
Flaps, flap revisions, wound revisions
Flaps
Overall, 31 patients underwent radial forearm flaps
(77.5%), 3 patients had fibula flaps (7.5%), 2 patients had
scapula flaps (5.0%), 1 patient received an arterialised ven-
ous flap of the forearm (2.5%) and 1 patient received a gra-
cilis muscle flap (2.5%). One patient received both fibula
and radial forearm flaps simultaneously (2.5%) and one pa-
tient received radial forearm flap and secondary ulnar fore-
arm flap as a consequence of flap necrosis (2.5%) (fig. 1).
Anastomosis revisions, flap wound revisions,
complications in the further course of treatment and flap
donor site complications
Anastomosis revision was performed in 3/40 patients
(7.5%) because of venous thrombosis (n = 1) and venous
bleeding/stasis (n = 2). Flap wound revisions were needed
in two patients owing to venous bleeding/stasis, and in two
patients because of partial necrosis of the flap and the need
for surgical debridement (10%). Nonsalvageable flap fail-
ure occurred in one patient as a result of arterial thrombosis
(2.5%), with unsuccessful revision, resulting in an overall
flap survival rate of 97.5%.
In the further course, 8 of 40 patients (20.0%) developed
complications including: fistula (1 patient), cervical
haematoma (4 patients), flap dehiscence (2 patients) and
wound healing impairment (1 patient).
Nine patients (22.5%) had flap donor site complications
including wound dehiscence (3 patients), haematoma with
need for vacuum-assisted closure therapy (1 patient),
wound infection with the need for antibiotic therapy (2 pa-
tients), prolonged wound healing (2 patients) and seroma
(1 patient).
After adjustment for potential difference in the prognostic
profile between patients either receiving a tracheotomy or
delayed postoperative extubation, the likelihood for com-
plications was nearly identical in the two groups (OR [95%
CI] 1.37 [0.26‒7.19], p = 0.710). Table 3 provides inform-
ation on flap-associated complications for the NO-TRACH
group and the PRIM-TRACH group separately, excluding
those patients with secondary tracheotomy.
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Survival and oncological outcomes
For the group as a whole, median follow up was 357 days
(IQR 193–483) with 1-year OS, DSS and ARFS of 92.5%,
94.9% and 79.9%, respectively.
When the two groups were compared, median follow-up
was 299 days (IQR 183–481) in the NO-TRACH group
compared with 384 days (IQR 276–475) in the PRIM-
TRACH group. One-year OS, DSS and ARFS were 95.7%,
95.7% and 89.1%, respectively, in the NO-TRACH group,
and 88.2%, 93.8% and 68.2%, respectively, in the PRIM-
TRACH (table 4). No significant difference between
groups was found for OS or DSS (OS: p = 0.89; DSS: p =
0.79). The NO-TRACH group showed a better ARFS than
the PRIM-TRACH group (p = 0.04).
Table 1: Patient demographic data and tumour characteristics for each group.
NO-TRACH (n = 23) PRIM-TRACH (n = 17)
Demographics
Mean age ± SD (years) 64.5 ± 11.0 65.8 ± 10.9
Female 5/23 (21.7%) 6/17 (35.3%)
Male 18/23 (78.3%) 11/17 (64.7%)
Range of age (years) 39–90 45–83
Tumour site
Lateral tongue 7/23 (30.4%) 1/17 (5.9%)
Base of tongue 2/17 (11.8%)
FOM 6/23 (26.1%) 1/17 (5.9%)
Buccal mucosa 4/23 (17.4%) 1/17 (5.9%)
Soft palate 2/23 (8.6%) 3/17 (17.6%)
Hard palate 1/17 (5.9%)
Palatine tonsils 1/17 (5.9%)
Alveolar ridge 1/17 (5.9%)
Oropharynx (pharynx wall) 1/23 (4.3%) 1/17 (5.9%)
Sublingual gland 1/23 (4.3%)
Parotid gland 2/23 (8.6%)
Larynx (subglottic and supraglottic) 2/17 (11.8%)
Hard palate and maxilla 1/17 (5.9%)
Floor of the nose 1/17 (5.9%)
Lips 1/17 (5.9%)
T stage
T1 7/23 (30.4%) 4/17 (23.5%)
T2 12/23 (52.2%) 3/17 (17.6%)
T3 2/23 (8.7%) 1/17 (5.9%)
T4 2/23 (8.7%) 7/17 (41.2%)
NOS 1/17 (5.9%)
N stage
N0 9/23 (39.1%) 11/17 (64.7%)
N1 7/23 (30.45%) 1/17 (5.9%)
N2 7/23 (30.45%) 4/17 (23.5%)
NOS 1/17 (11.8%)
TNM staging (I-IV)
Stage I 4/23 (17.4%) 3/17 (17.6%)
Stage II 4/23 (17.4%) 3/17 (17.6%)
Stage III 7/23 (30.4%) 2/17 (11.8%)
Stage IV 8/23 (34.8%) 7/17 (41.2%)
NOS 2/17 (11.8%)
Primary vs persistent / recurrent tumour
Primary tumour 22/23 (95.7%) 10/17 (58.8%)
Tumour persistence / recurrence 1/23 (4.3%) 7/17 (41.2%)
Histological workup
SCC 19 (82.7%) 14 (82.3%)
AC 3 (13%)
Acinus cell carcinoma 1 (4.3%)
MEC 1 (5.9%)
Spindle-cell like tumour maxilla 1 (5.9%)
Metastasis soft-tissue following adenocarcinoma 1 (5.9%)
Tracheotomy
Primary tracheotomy 17 (100%)
Secondary tracheotomy 3 (13%)
AC = adenocarcinoma; FOM = floor of the mouth; MEC = mucoepidermoid carcinoma; NO-TRACH = delayed extubation approach; NOS = not otherwise specified; PRIM-
TRACH = primary tracheotomy approach; SCC = squamous cell carcinoma; SD = standard deviation
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Discussion
Although this was not a prospective, randomised controlled
trial of tracheotomy versus no tracheotomy, we can say
with some confidence that not performing routine
tracheotomy in patients meeting the inclusion criteria for
the delayed extubation approach was safe. Secondary
tracheotomy was performed as a nonemergency procedure
in three patients, two because of a prolonged intensive care
stay due to cardiopulmonary problems and one whilst un-
dergoing revision of a neck haematoma. We noted sev-
eral benefits of not performing routine tracheotomy, in-
cluding shorter operation time, which can partially be ex-
plained by not performing tracheotomy, and additional pa-
tient comfort in terms of postoperative swallowing rehab-
ilitation. Furthermore, overall perioperative complications
were comparable in the two groups (NO-TRACH versus
PRIM-TRACH) with no perioperative airway complica-
tions occurring.
Our case series is typical for a tertiary referral centre with
squamous cell cancer (82.5%) being the most common dis-
ease and the oral cavity (60.0%) the most common primary
tumour site [13, 14]. Between April 2011 and January
2013, 40 HNC patients fitting the inclusion criteria for this
study underwent HNC resection and reconstruction with
MFTT at our department. Similar to other studies, the radi-
al forearm flap was the most commonly used flap (77.5%),
providing thin pliable skin with a highly reliable long ped-
icle [13–15]. This is ideal for reconstructing defects of the
oral mucosa, tongue and floor of mouth [13, 16]. Our flap
complication and failure rates are in line with other series,
which reported flap survival rates of between 91.6% and
99.3% [13, 14, 17].
Optimal airway management in HNC patients undergoing
MFTT is controversial. The traditional thinking is that the
more major the procedure, the more a tracheotomy is in-
dicated. Procedures requiring MFTT are by definition very
major and long procedures, which would fall into this high
risk group [11]. Laryngopharyngeal oedema, posterior
Table 2: Intraoperative and perioperative characteristics for NO-TRACH patients and PRIM-TRACH patients.
NO-TRACH PRIM-TRACH p-value
Mean duration of surgery, SD (hours) 8.2 ± 1.6 10.4 ± 2.7 p = 0.001
Median time in ICU, IQR (days) 1.0 (1–2) 2.0 (1–3) p = 0.27
Median time in IMCU, IQR (days) 1.0 (1–1) 1.0 (1–2) p = 0.58
Median duration of artificial nutrition, IQR (days) 9.0 (8–18) 15.0 (9–55) p = 0.07
Median duration of hospitalisation, IQR (days) 15.0 (10–21) 18.0 (14–22) p = 0.14
ICU = intensive care unit, IMCU = intermediate care unit; IQR = interquartile range; NO-TRACH = delayed extubation approach; PRIM-TRACH = primary tracheotomy
approach; SD = standard deviation
Table 3: Flap-associated complications for the NO-TRACH and the PRIM-TRACH groups.
NO-TRACH PRIM-TRACH p-value
Flap failure
Arterial thrombosis n = 1
Anastomosis revision
Venous bleeding/stasis n = 2
Venous thrombosis n = 1
Flap wound revision
Partial necrosis n = 1
Venous bleeding/stasis n = 1
Complications in the further course of treatment
Cervical haematoma n = 2 n = 2
Flap dehiscence n = 2
Fistula n = 1
Wound healing disorder n = 1
Complications flap donor site
Dehiscence n = 2 n = 1
Infection n = 1 n = 1
Wound healing disorder n = 2
Seroma n = 1
Haematoma n = 1
p = 0.710*
NO-TRACH = delayed extubation approach; PRIM-TRACH = primary tracheotomy approach
* Intergroup differences were corrected for age, gender and tumour-stage, excluding those patients with secondary tracheotomy.
Table 4: Outcome measures for each group.
NO-TRACH (n = 23) PRIM-TRACH (n = 17)
Median follow-up, IQR (days) 299 (183–481) 384 (276–475)
Number of events, 1–year overall survival (%) 1/23 (95.7%) 2/17 (88.2%)*
Number of events, 1–year disease specific survival (%) 1/23 (95.7%) 1/17 (93.8%)#
Number of events, 1–year any recurrence free survival (%) 2/23 (89.1%) 5/17 (68.3%)†
IQR = interquartile range; NO-TRACH = delayed extubation approach; PRIM-TRACH = primary tracheotomy approach
* p = 0.89 vs NO-TRACH; # p = 0.79 vs NO-TRACH; † p = 0.04 vs NO-TRACH
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tongue oedema, retained secretions or swelling of the free
flap within the first postoperative days can be life threat-
ening, and primary tracheotomy is a proven and reliable
method for securing the airway. Thus, patients undergoing
a transmandibular approach, segmental mandibular resec-
tion, maxillectomy or laryngopharyngectomy are treated
with routine tracheotomy. In this particular subgroup of pa-
tients, either the risk of postoperative airway compromise
clearly exceeds the benefit of not performing tracheotomy
or the surgical procedure requires tracheotomy anyway.
However, although tracheotomy usually allows reasonable
functional rehabilitation with respect to speech and swal-
lowing [10], it complicates postoperative rehabilitation,
generates additional discomfort for the patient, and pre-
cludes patient independence in a subpopulation of patients.
Furthermore, patients are confronted with additional risks,
such as haemorrhage, obstruction, cannula displacement,
local infection, pulmonary infection, fistula, tracheal sten-
osis and tumour seeding [6, 9].
Our current regimen is to avoid routine tracheotomy when
reasonable and when meeting the above mentioned inclu-
sion criteria. Patients with the need for MFTT to the floor
of mouth or the tongue especially can often be safely man-
aged without tracheotomy. Postoperatively, patients remain
intubated until the first postoperative day and then, fol-
lowing extubation, proceed to the IMCU for further close
monitoring. Usually 12 to 24 hours later, patients can be
transferred to the regular ward and undergo routine rehabil-
itation. None of our patients suffered life-threatening peri-
operative airway complications and overall perioperative
complication rates were similar between the two groups.
This shows our approach to be safe. Our results also show
that NO-TRACH patients remained intubated for an aver-
age of 1.1 days, which indicates our postoperative regimen
of airway management to be efficient.
Lastly, our results show a decreased duration of surgery, a
trend to earlier resumption of oral feeding and shortened
overall hospital stay in the NO-TRACH group. Although
duration of surgery, dependence on artificial nutrition and
postoperative hospitalisation time are influenced by vari-
ous cofactors, especially by the complexity of the surgical
procedure, disease stage and comorbidities of the patients,
our approach supports current efforts to concurrently op-
timise postoperative patient rehabilitation and clinical cost
effectiveness.
Our results reflect a single-centre experience based on a
small number of patients. Thus, generalisation of our find-
ings needs to be proven in further studies. The observation
period was characterised by consecutive patients under-
going MFTT with (before April 2012) and without (after
April 2012) routine tracheotomy. Therefore, a certain gain
of know-how and experience in the peri- and post-oper-
ative care of these patients may favour the NO-TRACH
group.
We are aware of the fact that intergroup comparison (NO-
TRACH group vs PRIM-TRACH group) must be inter-
preted with caution, because of the heterogeneous initial
risk profiles of the two cohorts resulting from differences
in comorbidities, distribution of primary tumour sites and,
especially, TNM stage. TNM staging of the PRIM-TRACH
group revealed a trend to more advanced disease with a
higher rate of salvage procedures, when compared with
the NO-TRACH group. This is reflected by a lower ARFS
compared with the NO-TRACH group. We therefore reran
our analysis excluding all the salvage patients and once
again found that mean duration of surgery was significantly
shorter in the NO-TRACH group and again we observed
trends to shorter ICU stay and hospital length of stay. Sur-
vival analysis was similar to the results found when not
excluding the salvage patients, although the small number
of events in the survival analysis limits its significance.
Indeed, the only difference from our original results was
that the resumption of oral feeding no longer showed any
difference between the two groups.
Conclusion
Even in patients undergoing major HNC resection and
MFTT, tracheotomy should not be considered routine. We
suggest that each case should be assessed on its own merits.
Despite our small cohort size, we show encouraging func-
tional results using a delayed extubation approach, without
adverse perioperative or oncological impact. We emphas-
ise, however, that NO-TRACH patients need to be closely
monitored postoperatively to ensure the safety of this ap-
proach. Further work, ideally in the setting of a large pro-
spective randomised clinical trial, is needed to confirm our
findings.
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Figures (large format)
Figure 1
Distribution of flap donor sites in all reviewed patients undergoing microvascular free tissue transfer.
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